Outcomes of first-line FOLFIRINOX (FFX) versus gemcitabine and nab-paclitaxel (GN) in patients with advanced pancreatic cancer: Multi-Institutional Canadian sites experience

Neha Papneja(McGill University), Petr Kavan(Université Paris Cité), Ivan Barrera, Gerald Batist(Jewish General Hospital), Shahid Ahmed(Emory University), P. Mondal, Abhishek Papneja
Annals of Oncology
October 1, 2019
10.1093/annonc/mdz247.028
Cited by 1

Related Papers

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
|Cancers|2023|640
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Gallbladder Cancer in the 21st Century
|Journal of Oncology|2015|301